Regulatory Growing Pains: An Interview With King CEO Brian Markison (Part 2)

King Pharmaceuticals is in the center of a pivotal shift in the regulation of addictive pain therapies in the U.S. The company hopes to keep getting new products through FDA while helping to shape a class-wide opioid REMS. That is quite an agenda for 2010.